MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

866.626.6847

Dimethyl Fumarate

Selected References:

  • Amato MP, et al. 2015. Fertility, pregnancy and childbirth in patients with multiple sclerosis: Impact of disease-modifying drugs. CNS Drugs. 29:207–220.
  • Andersen JB, et al. 2023. Pregnancy outcomes after early fetal exposure to injectable first-line treatments, dimethyl fumarate, or natalizumab in Danish women with multiple sclerosis. Eur J Neurol 30(1):162-171.
  • Bridel C, et al. 2014. Update on multiple sclerosis treatments. Swiss Med Wkly. 144:w14012.
  • Ciplea AI, et al. 2020. Dimethyl fumarate transfer into breast milk. Ther Adv Neurol Disord. 13:1756286420968414.
  • Gold R, et al. 2015. Delayed-release dimethyl fumarate and pregnancy: Preclinical studies and pregnancy outcomes from clinical trials and postmarketing experience. Neurol Ther. 4(2):93-104.
  • Hellwig K, et al. 2024. Final analysis of 379 pregnancy outcomes after exposure to dimethyl fumarate in a prospective international registry. Mult Scler 30(2):209-215.
  • Landi D, et al. 2024. Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy. Mult Scler 30(11-12):1503-1513.
  • Leroy C, et al. 2015. Immunosuppressive drugs and fertility. Orphanet J Rare Dis. 10:136.
  • Lu E, et al. 2014. A review of safety-related pregnancy data surrounding the oral disease-modifying drugs for multiple sclerosis. CNS Drugs; 28(2):89-94.
  • Moccia M, et al. 2023. Fertility, pregnancy and childbirth in women with multiple sclerosis: a population-based study from 2018 to 2020. J Neurol Neurosurg Psychiatry.94(9):689-697.
  • Tecfidera prescribing information. 2024. Available online at: https://www.tecfiderahcp.com/content/dam/commercial/multiple-sclerosis/tecfidera/hcp/en_us/pdf/Tecfidera_PI.pdf.
  • Van Neste M, et al. 20 Very low monomethyl fumarate exposure via human milk: a case report-a contribution from the ConcePTION project. Front Public Health. 2;12:1393752.
  • Yeh WZ, et al. 2021. Natalizumab, fingolimod and dimethyl fumarate use and pregnancy-related relapse and disability in women with multiple sclerosis. Neurology. 96(24):e2989-e3002.

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.